This research aims to identify and characterize new benzamide derivatives as SUCNR1 antagonists for cancer treatment.
Discovery of benzamide derivatives as lead candidates
Characterization of their antagonist properties
Evaluation of their effectiveness in immuno-oncology
Demonstrated high potency of benzamide derivatives as SUCNR1 antagonists
Provided evidence supporting SUCNR1 antagonism as a viable strategy in cancer immunotherapy
Abstract
as a lead candidate for targeting SUCNR1 but also provides compelling evidence for SUCNR1 antagonism as a potent therapeutic approach in immuno-oncology.